{"page_content": "Product Candidate Preclinical Phase 1 Phase 2 Phase 3 Registration\nDasiglucagon Mini-Dose Pen\nDasiglucagon Bihormonal Artificial PancreasDasiglucagon SC Continuous InfusionGlepaglutide (GLP-2 Analog)BI 456906  \n(GLP-1/GLU Dual Agonist)\u00b9\nZP8396 (Amylin Analog)ZP6590 (GIP Agonist)Dapiglutide (GLP-1/GLP-2 Dual Agonist)ZP9830 (Kv1.3 Ion Channel Blocker)ZP10000 (\u02514\u03b27 Integrin Inhibitor)Complement C3 Inhibitor\u00b2Zealand Pharma \nPipeline\nType 1 diabetes Rare disease Obesity\nGIP, glucose-dependent insulinotropic polypeptide; GLP, glucagon-like peptide; GLU, glucagon; hypo, hypoglycemia; IBD, inflammatory bowel disease; NASH, non-alcoholic steatohepatitis; \nSBS, short bowel syndrome; SC, subcutaneous; T1D, type 1 diabetes; T2D, type 2 diabetes; Undiscl., undisclosed\nInflammationType 1 Diabetes  \nExercise-Induced Hypoglycemia\nObesity, NASH and T2D\nObesity and T2D\nSBSObesity\nIBD\nIBD\nUndiscl.Type 1 Diabetes management\nCongenital Hyperinsulinism\nShort Bowel Syndrome19\nZealand Pharma  \u221e  Annual Report 2021Zealand Pharma Pipeline", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 18, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}